UA125600C2 - Лікування холестатичного свербежу - Google Patents

Лікування холестатичного свербежу Download PDF

Info

Publication number
UA125600C2
UA125600C2 UAA202001861A UAA202001861A UA125600C2 UA 125600 C2 UA125600 C2 UA 125600C2 UA A202001861 A UAA202001861 A UA A202001861A UA A202001861 A UAA202001861 A UA A202001861A UA 125600 C2 UA125600 C2 UA 125600C2
Authority
UA
Ukraine
Prior art keywords
pruritus
seladelpar
day
cholestatic
treatment
Prior art date
Application number
UAA202001861A
Other languages
English (en)
Ukrainian (uk)
Inventor
Пол Буд
Чарлз А. МакВертер
Александра С. Стейнберг
Original Assignee
Сімабей Терапьютікс, Інк.
Симабей Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сімабей Терапьютікс, Інк., Симабей Терапьютикс, Инк. filed Critical Сімабей Терапьютікс, Інк.
Publication of UA125600C2 publication Critical patent/UA125600C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Ladders (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
UAA202001861A 2017-09-26 2018-09-24 Лікування холестатичного свербежу UA125600C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762563395P 2017-09-26 2017-09-26
PCT/US2018/052490 WO2019067373A1 (en) 2017-09-26 2018-09-24 TREATMENT OF CHOLESTATIC PRURIT

Publications (1)

Publication Number Publication Date
UA125600C2 true UA125600C2 (uk) 2022-04-27

Family

ID=64564950

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA202001861A UA125600C2 (uk) 2017-09-26 2018-09-24 Лікування холестатичного свербежу

Country Status (26)

Country Link
US (2) US20190105291A1 (enExample)
EP (3) EP3687523B1 (enExample)
JP (1) JP7023371B2 (enExample)
KR (1) KR102376794B1 (enExample)
CN (1) CN111132675B (enExample)
AU (2) AU2018342323B2 (enExample)
BR (1) BR112020005074A2 (enExample)
CA (1) CA3076614C (enExample)
CY (1) CY1124894T1 (enExample)
DK (1) DK3973959T3 (enExample)
ES (2) ES3012120T3 (enExample)
FI (1) FI3973959T3 (enExample)
HR (2) HRP20250022T1 (enExample)
HU (2) HUE070033T2 (enExample)
IL (2) IL273569B (enExample)
LT (2) LT3973959T (enExample)
MX (1) MX392537B (enExample)
PL (2) PL3973959T3 (enExample)
PT (2) PT3687523T (enExample)
RS (1) RS62790B1 (enExample)
SG (1) SG11202002253SA (enExample)
SI (2) SI3687523T1 (enExample)
SM (1) SMT202200171T1 (enExample)
UA (1) UA125600C2 (enExample)
WO (1) WO2019067373A1 (enExample)
ZA (1) ZA202001646B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
ES2701094T3 (es) 2014-03-20 2019-02-20 Cymabay Therapeutics Inc Tratamiento de enfermedades colestáticas intrahepáticas
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
KR20210078515A (ko) 2018-10-18 2021-06-28 아비어, 인크. 만성 신장 질환-연관 소양증의 치료 방법 및 장치
KR20220140762A (ko) * 2020-02-10 2022-10-18 장피트 엘라피브라노에 의한 원발 담즙성 담관염의 치료
CN115884765A (zh) 2020-08-26 2023-03-31 基恩菲特公司 用于治疗原发性胆汁性胆管炎的组合物和方法
CN116490191A (zh) * 2020-10-20 2023-07-25 葛兰素史克知识产权第二有限公司 治疗胆汁淤积性瘙痒的方法
RS65546B1 (sr) 2021-02-01 2024-06-28 Cymabay Therapeutics Inc Tretman holangiopatija sa seladelparom
US20240252499A1 (en) 2023-01-29 2024-08-01 Cymabay Therapeutics, Inc. Treatment of uremic pruritus
KR20250139304A (ko) * 2023-01-29 2025-09-23 사이머베이 쎄라퓨틱스, 인코퍼레이티드 만성 소양증 피부병의 치료
WO2025250635A1 (en) * 2024-05-28 2025-12-04 Avior, Inc. Use of nalmefene hydrochloride buccal films in treating liver disease associated pruritus
WO2026030533A1 (en) 2024-07-31 2026-02-05 Cymabay Therapeutics, Inc. Seladelpar for use in treating liver disease
US20260207538A1 (en) 2024-12-20 2026-07-23 Gilead Sciences, Inc. Combinations for liver disease
CN121023009A (zh) * 2025-10-31 2025-11-28 浙江大学医学院附属妇产科医院(浙江省妇女医院、浙江省妇女保健院) 基于唾液样本的妊娠期肝内胆汁淤积症易感基因多重pcr—ngs筛查方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA87467C2 (xx) 2003-09-19 2009-07-27 Янссен Фармацевтика Н.В 4-((феноксіалкіл)тіо)феноксіоцтова кислота та її аналоги$4-((феноксиалкил)тио)феноксиуксусная кислота и ее аналоги
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
ES2701094T3 (es) * 2014-03-20 2019-02-20 Cymabay Therapeutics Inc Tratamiento de enfermedades colestáticas intrahepáticas
JP2020533339A (ja) * 2017-09-13 2020-11-19 ノバルティス アーゲー Fxrアゴニストを含む組合せ

Also Published As

Publication number Publication date
EP3973959B1 (en) 2024-12-11
RU2020114644A (ru) 2021-10-27
US20190105291A1 (en) 2019-04-11
MX2020007273A (es) 2022-05-23
CA3076614C (en) 2023-02-07
IL288340B2 (en) 2023-05-01
WO2019067373A1 (en) 2019-04-04
SG11202002253SA (en) 2020-04-29
AU2021254641A1 (en) 2021-11-18
CY1124894T1 (el) 2023-01-05
ES2902349T3 (es) 2022-03-28
HUE070033T2 (hu) 2025-05-28
HRP20212010T1 (hr) 2022-04-01
LT3687523T (lt) 2022-03-25
EP4523744A3 (en) 2025-06-04
PL3687523T3 (pl) 2022-02-21
CN111132675A (zh) 2020-05-08
PL3973959T3 (pl) 2025-03-24
DK3973959T3 (da) 2025-01-20
LT3973959T (lt) 2025-01-10
AU2021254641B2 (en) 2022-02-24
FI3973959T3 (fi) 2025-02-03
IL273569A (en) 2020-05-31
EP3973959A1 (en) 2022-03-30
AU2018342323A1 (en) 2020-04-16
SMT202200171T1 (it) 2022-05-12
US20210283078A1 (en) 2021-09-16
EP4523744A2 (en) 2025-03-19
HRP20250022T1 (hr) 2025-03-14
HUE057377T2 (hu) 2022-05-28
IL288340B1 (en) 2023-01-01
EP3973959B8 (en) 2025-01-15
ZA202001646B (en) 2021-08-25
SI3973959T1 (sl) 2025-03-31
AU2018342323B2 (en) 2021-09-23
KR20200058458A (ko) 2020-05-27
PT3973959T (pt) 2025-01-24
BR112020005074A2 (pt) 2020-09-15
SI3687523T1 (sl) 2022-05-31
MX392537B (es) 2025-03-04
EP3687523B1 (en) 2021-11-03
IL288340A (en) 2022-01-01
PT3687523T (pt) 2021-12-06
EP3687523A1 (en) 2020-08-05
ES3012120T3 (en) 2025-04-08
NZ762976A (en) 2021-11-26
IL273569B (en) 2021-12-01
CA3076614A1 (en) 2019-04-04
JP2020535225A (ja) 2020-12-03
KR102376794B1 (ko) 2022-03-18
RU2020114644A3 (enExample) 2022-02-14
JP7023371B2 (ja) 2022-02-21
CN111132675B (zh) 2023-04-25
RS62790B1 (sr) 2022-02-28

Similar Documents

Publication Publication Date Title
AU2021254641B2 (en) Treatment of cholestatic pruritus
EP3119384B1 (en) Treatment of intrahepatic cholestatic diseases
JPS6241688B2 (enExample)
JP7079735B2 (ja) 肝内胆汁うっ滞性疾患の処置
US11224580B2 (en) Treatment of intrahepatic cholestatic diseases
WO2001032166A1 (en) NEW COMBINATION COMPRISING A β2-ADRENORECEPTOR AGONIST AND A LEUKOTRIENE RECEPTOR ANTAGONIST
HK40062783B (en) Treatment of cholestatic pruritus with seladelpar
HK40121699A (en) Treatment of cholestatic pruritus
RU2781281C2 (ru) Лечение холестатического зуда
HK40062783A (en) Treatment of cholestatic pruritus with seladelpar
HK40033446B (en) Treatment of cholestatic pruritus with seladelpar
HK40033446A (en) Treatment of cholestatic pruritus with seladelpar
BR122026005517A2 (pt) Uso de seladelpar ou um sal do mesmo no tratamento de prurido colestático, composição e kit
NZ762976B2 (en) Treatment of cholestatic pruritus
HK1229212A1 (en) Treatment of intrahepatic cholestatic diseases
HK1229212B (en) Treatment of intrahepatic cholestatic diseases
WO2013036844A2 (en) Methods for treatment of and prophylaxis against hemorrhoids